Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
Provided By GlobeNewswire
Last update: Jul 29, 2025
On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177
On track to complete enrollment of the first cohort of Phase 1 ‘HEAT’ trial of RAD202 for treatment of advanced HER2-positive solid tumors
Read more at globenewswire.comNASDAQ:RADX (12/12/2025, 8:00:01 PM)
4.26
-0.02 (-0.47%)
Find more stocks in the Stock Screener
